Abbott Laboratories’s Stock Price Skyrockets to $131.35, Posting a Robust 3.74% Gain

Abbott Laboratories (ABT)

131.35 USD +4.74 (+3.74%) Volume: 8.44M

Abbott Laboratories’s stock price soars to $131.35, marking a significant trading session increase of +3.74%, with a robust trading volume of 8.44M. The company’s stock continues its upward trajectory with an impressive YTD performance, boasting a percentage change of +16.13%.

Latest developments on Abbott Laboratories

Abbott Laboratories‘ stock has been outperforming competitors on a strong trading day, with BTIG maintaining a Buy rating and a $140 target for the company. Abbott’s Volt has entered the Pulsed Field Ablation market with a CE mark, gaining approval from European regulators. The company’s new AFib device has also received early approval from European regulators, showing a 99% success rate. Abbott has been making significant strides in the PFA market, with Diamond Hill Capital expressing strong interest in the company. Despite falling behind the market at times, Abbott continues to accelerate competition in Europe with its Volt PFA system gaining CE Mark approval for AFib treatment. Oppenheimer maintains a target of $134 for Abbott Laboratories, highlighting the company’s positive options trends and advancements in the medical field.

Abbott Laboratories on Smartkarma

Analysts from Baptista Research on Smartkarma have provided insightful coverage on Abbott Laboratories, highlighting the company’s strong financial performance in the fourth quarter of 2024. Excluding COVID-19 testing, Abbott reported a solid sales growth of 10%, contributing to a full-year increase of 9.5%. The growth was driven by progress in business segments like Adult Nutrition and Medical Devices, including continuous glucose monitoring systems. Despite these positive trends, the analysts caution that this may not be enough to warrant a ‘Buy’ rating on the company.

In another report by Baptista Research on Smartkarma, analysts discuss Abbott Laboratories‘ performance in the third quarter of 2024, showcasing organic sales growth of over 8% excluding COVID testing sales. The company also reported adjusted earnings per share of $1.21, demonstrating its ability to execute its strategy effectively across different sectors. Particularly, the U.S. Pediatric Nutrition segment saw significant growth with a 12% increase driven by gains in the infant formula business. These reports provide valuable insights for investors considering Abbott Laboratories as a potential investment.

A look at Abbott Laboratories Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Abbott Laboratories has a positive long-term outlook. The company scores high in Dividend and Growth, indicating strong potential for future returns and growth. Additionally, Abbott Laboratories has a high Momentum score, suggesting that the company is currently performing well in the market. However, the Resilience score is lower, which may indicate some potential risks or challenges ahead.

Abbott Laboratories is known for its wide range of healthcare products and services, including pharmaceuticals, nutritional, diagnostics, and vascular products. With a solid Value score and strong performance in Dividend, Growth, and Momentum, Abbott Laboratories appears to be well-positioned for continued success in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma